Research in the Division of Pharmacology
- 11 Downloads
Within the Center for Bio-Pharmaceutical Sciences pharmacological research has its emphasis on kinetics of drug disposition, and its interrelationship with pharmacodynamics. The benzodiazepines present a class of related compounds where comparative studies have been performed. Both in humans and in animal models the relationship between plasma levels and central effects has been studied. Also the factors that influence individual responses to the same dose of a drug have been investigated. One of the approaches is the predictive value of antipyrine metabolite formation. Nifedipine shows polymorphism in oxidation, but it is possible to obtain the desired pharmacodynamic effect while minimizing side effects even in slow metabolizers.
KeywordsPublic Health Internal Medicine Animal Model Plasma Level Nifedipine
Unable to display preview. Download preview PDF.
- 1.Breimer DD. Developments in clinical pharmacokinetics 1981–1983. In: Aiache JM, Hirtz J, eds. 2nd European Congress of Biopharmaceutics and Pharmacokinetics. Paris: Technique et Documentation, 1984. Vol. 3.Google Scholar
- 2.Breimer DD, Jochemsen R, Von Albert HH. Pharmacokinetics of benzodiazepines: Short-acting versus long-acting. Arzneim Forsch 1980;30:875–81.Google Scholar
- 6.Breimer DD, Jochemsen R, Kamphuisen HAC, Nicholson AN, Spencer MB, Stone BM. Central effects during the continuous osmotic infusion of a benzodiazepine (triazolam). Br J Clin Pharmacol (in press).Google Scholar
- 8.Dingemanse J, Breimer DD. Benzodiazepine receptors. Pharmacy International 1984;5:33–6.Google Scholar
- 9.Breimer DD, Danhof M. Interindividual differences in pharmacokinetics and drug metabolism. In: Breimer DD, ed. Towards Better Safety of Drugs and Pharmaceutical Products. Amsterdam: Elsevier/North-Holland Biomedical Press, 1980:117–42.Google Scholar
- 10.Danhof M, Teunissen MWE. Antipyrine as a model drug to assess oxidative drug metabolizing activity in man. Pharmacy International 1984;5:11–5.Google Scholar
- 15.Teunissen MWE, De Leede LGJ, Boeijinga JK, Breimer DD. Correlation between antipyrine metabolite formation and theophylline metabolism in man after simultaneous single dose administration and at steadystate. J Pharmacol Exp Ther (in press).Google Scholar
- 16.Kleinbloesem CH, Van Brummelen P, Faber H, Danhof M, Vermeulen NPE, Breimer DD. Variability in nifedipine pharmacokinetics and dynamics: A new oxidation polymorphism in man. Biochem Pharmacol 1984;22:3721–4.Google Scholar
- 18.Kleinbloesem CH, Van Brummelen P, Van Harten J, Danhof M, Breimer DD. Nifedipine: Influence of renal function on pharmacokinetic/haemodynamic relationship. Clin Pharmacol Ther (in press).Google Scholar
- 20.De Leede LGJ, De Boer AG, Feijen CD, Breimer DD. Site-specific rectal drug administration in man with an osmotic system: influence of ‘first-pass’ elimination of lidocaine. Pharm Res 1984;3:129–34.Google Scholar
- 21.Breimer DD, De Leede LGJ, De Boer AG. New drug delivery systems as tools in clinical pharmacology. In: Lemberger L, Reidenberg MM, eds. Proceedings 2nd World Conference on Clinical Pharmacology and Therapeutics. Bethesda: American Society of Pharmacology & Experimental Therapeutics, 1984:431–43.Google Scholar